

## 5-Fluorouracil (5 day) and mitoMYcin Chemoradiation Therapy

### INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Treatment of muscle invasive bladder cancer in patients	C67	00450a	Hospital

### TREATMENT:

*The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.*

mitoMYcin is administered at a dose of 12mg/m<sup>2</sup> on day 1 only.

5-fluorouracil (5-FU) is administered at a dose of 500mg/m<sup>2</sup>/day on days 1–5 (week 1) and days 22-26 (week 4) corresponding to fractions 1-5 and 16-20 of radiotherapy for 1 cycle.

Day	Drug	Dose	Route and Method of Administration	Diluent & Rate
1	mitoMYcin	12mg/m <sup>2</sup>	IV Bolus	
1-5, 22-26	5-Fluorouracil <sup>a</sup>	500mg/m <sup>2</sup> /day (Total dose = 2500mg/m <sup>2</sup> over 120 hours)	Continuous IV infusion over 5 days	Infusor pump

<sup>a</sup>See dose modifications section for patients with identified partial DPD deficiency

### ELIGIBILITY:

- Indications as above
- ECOG status 0-2

### EXCLUSIONS:

- Hypersensitivity to 5- fluorouracil, mitoMYcin or any of the excipients
- Pregnancy
- Breast Feeding
- Known complete DPD deficiency

### PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

NCCP Regimen, Fluorouracil (5 day) and mitoMYcin Chemoradiation Therapy	Published: 17/11/2017 Review: 06/11/2021	Version number: 3
Tumour Group: Genitourinary NCCP Regimen Code: 00450	ISMO Contributor: Prof Maccon Keane	Page 1 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p style="text-align: center;"><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## TESTS:

### Baseline tests:

- FBC, renal and liver profile
- DPD testing prior to first treatment with 5-Fluorouracil using phenotype and/or genotype testing unless patient has been previously tested

### Regular tests:

- FBC, renal and liver profile weekly throughout treatment

### Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

## DOSE MODIFICATIONS:

- Consider a reduced starting dose in patients with identified partial DPD deficiency.
  - Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring.
- Any dose modification should be discussed with a Consultant

## Haematological:

**Table 1: Dose Modification for Haematological toxicity**

ANC (x 10 <sup>9</sup> /L) ( on day of chemotherapy)		Platelets (x 10 <sup>9</sup> /L) ( at any stage during cycle)	Dose Modification
≥1	and	≥ 100	100%
0.5-0.99	or	50-99	Delay treatment until recovery
<0.5	or	<50	Delay treatment until recovery and consider reducing fluorouracil by 25% for subsequent cycles
Febrile neutropenia			

## Renal and Hepatic Impairment:

**Table 2: Dose Modification in Renal and Hepatic Impairment**

Drug	Renal Impairment		Hepatic Impairment			
	CrCl (ml/min)	Dose	Bilirubin	AST	Dose	
5-Fluorouracil	Consider dose reduction in severe renal impairment only		<85		<180	100%
			>85	or	>180	Cl
			Clinical decision. Moderate hepatic impairment; reduce initial dose by 1/3.			
			Severe hepatic impairment, reduce initial dose by 1/2.			
mitoMYcin	>10	100%	Dose reductions probably not necessary – clinical decision when AST levels > 2 x ULN.			
	<10	75%				
	Consider a dose reduction for high doses of mitomycin when GFR 10-60ml/min.					

NCCP Regimen, Fluorouracil (5 day) and mitoMYcin Chemoradiation Therapy	Published: 17/11/2017 Review: 06/11/2021	Version number: 3
Tumour Group: Genitourinary NCCP Regimen Code: 00450	ISMO Contributor: Prof Maccon Keane	Page 2 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## Non-Haematological Toxicity:

**Table 3: Dose modification of 5-fluorouracil for adverse events**

Adverse Event	Dose modification of 5 Fluorouracil
Diarrhoea or Mucositis Grade 2 Grade ≥ 3	Delay treatment until toxicity has resolved to Grade 1 or less Delay treatment until toxicity has resolved to Grade 1 or less and reduce fluorouracil by 50% for subsequent cycles

## SUPPORTIVE CARE:

### EMETOGENIC POTENTIAL:

5-Fluorouracil Low (Refer to local policy).  
mitoMYcin Low (Refer to local policy).

**PREMEDICATIONS:** Not required

### OTHER SUPPORTIVE CARE:

Anti-diarrhoeal treatment (Refer to local policy).  
Mouth Care (Refer to local policy)

## ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

*The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details*

- **Extravasation:** mitoMYcin causes pain and tissue necrosis if extravasated (Refer to local policy)
- **Neutropenia :** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Myocardial ischaemia and angina:** Cardiotoxicity is a serious complication during treatment with fluorouracil. Patients, especially those with a prior history of cardiac disease or other risk factors, treated with fluorouracil, should be carefully monitored during therapy.
- **Dihydropyrimidine dehydrogenase (DPD) deficiency:** DPD is an enzyme encoded by the DPYD gene which is responsible for the breakdown of fluoropyrimidines. Patients with DPD deficiency are therefore at increased risk of fluoropyrimidine-related toxicity, including for example stomatitis, diarrhoea, mucosal inflammation, neutropenia and neurotoxicity. Treatment with 5-Fluorouracil, capecitabine or tegafur-containing medicinal products is contraindicated in patients with known complete DPD deficiency. Consider a reduced starting dose in patients with identified partial DPD deficiency. Initial dose reduction may impact the efficacy of treatment. In the absence of serious toxicity, subsequent doses may be increased with careful monitoring. Therapeutic drug monitoring (TDM) of fluorouracil may improve clinical outcomes in patients receiving continuous 5-fluorouracil infusions.
- **Hand-foot syndrome (HFS),** also known as palmar-plantar erythrodysesthesia (PPE) has been reported as an unusual complication of high dose bolus or protracted continuous therapy for 5-fluorouracil.

NCCP Regimen, Fluorouracil (5 day) and mitoMYcin Chemoradiation Therapy	Published: 17/11/2017 Review: 06/11/2021	Version number: 3
Tumour Group: Genitourinary NCCP Regimen Code: 00450	ISMO Contributor: Prof Maccon Keane	Page 3 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a>  <i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## DRUG INTERACTIONS:

- Marked elevations of prothrombin time and INR have been reported in patients stabilized on warfarin therapy following initiation of fluorouracil regimes.
- Concurrent administration of fluorouracil and phenytoin may result in increased serum levels of phenytoin
- 5- Fluorouracil is contraindicated in combination with brivudin, sorivudin and analogues as these are potent inhibitors of the 5-fluorouracil metabolising enzyme dihydropyrimidine dehydrogenase (DPD).
- Caution should be taken when using fluorouracil in conjunction with medications which may affect dihydropyrimidine dehydrogenase activity.
- Current drug interaction databases should be consulted for more information.

## ATC CODE:

5-Fluorouracil - L01BC02  
 mitoMYcin - L01DC03

## REFERENCES:

1. James ND, Hussain SA, Hall E. et al. Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. *N Engl J Med*; 2012;366;16: 1477-88.
2. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network .Available at <http://londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-cytotoxics.pdf>
3. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009;North London Cancer Network. Available at <http://londoncancer.org/media/65594/hepatic-impairment-dosage-adjustment-for-cytotoxics.pdf>
4. Mitomycin-C Kyowa 10 mg. SmPC HPRA. Last updated: 20/02/2019. Accessed: Nov 2019. Available at: [https://www.hpra.ie/img/uploaded/swedocuments/Final\\_PA2288-002-001\\_20022019120937.pdf](https://www.hpra.ie/img/uploaded/swedocuments/Final_PA2288-002-001_20022019120937.pdf)
5. [HPRA](#) Direct Healthcare Professional Communication. 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity. Accessed Aug 2020 Available at: [https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-\(i-v\)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0](https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information-from-marketing-authorisation-holders-of-products-containing-5-fluorouracil-(i-v)-capecitabine-and-tegafur-as-approved-by-the-hpra.pdf?sfvrsn=0)
6. Fluorouracil 50 mg/ml Solution for Injection or Infusion SmPC HPRA. Last updated: 10/05/2019. Accessed Nov 2019. Available at; [https://www.hpra.ie/img/uploaded/swedocuments/Licence\\_PA2315-091-001\\_10052019144741.pdf](https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2315-091-001_10052019144741.pdf)

NCCP Regimen, Fluorouracil (5 day) and mitoMYcin Chemoradiation Therapy	Published: 17/11/2017 Review: 06/11/2021	Version number: 3
Tumour Group: Genitourinary NCCP Regimen Code: 00450	ISMO Contributor: Prof Maccon Keane	Page 4 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a>  <i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

Version	Date	Amendment	Approved By
1	15/11/2017		Prof Maccon Keane
2	06/11/2019	Reviewed. Updated exclusions, emetogenic potential and drug interactions.	Prof Maccon Keane
3	1/9/2020	Updated exclusion criteria, baseline testing, dose modifications and adverse events with respect to DPD deficiency as per DHPC from HPRA June 2020 Updated Adverse events regarding palmar-plantar erythrodysesthesia	Prof Maccon Keane

Comments and feedback welcome at [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie).

NCCP Regimen, Fluorouracil (5 day) and mitoMYcin Chemoradiation Therapy	Published: 17/11/2017 Review: 06/11/2021	Version number: 3
Tumour Group: Genitourinary NCCP Regimen Code: 00450	ISMO Contributor: Prof Maccon Keane	Page 5 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a>  <i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		